{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:37:15Z","timestamp":1787312235972,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Abbie G.K."},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AYUMI Pharmaceutical companies"},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Pharmaceutical K.K."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi UCB Japan"},{"name":"Teijin Healthcare Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00296-021-04862-y","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T12:31:08Z","timestamp":1619440268000},"page":"1233-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-8205","authenticated-orcid":false,"given":"Yuichi","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-3154","authenticated-orcid":false,"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-3196","authenticated-orcid":false,"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-2884","authenticated-orcid":false,"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3120-1273","authenticated-orcid":false,"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-183X","authenticated-orcid":false,"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-7238","authenticated-orcid":false,"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7117","authenticated-orcid":false,"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"9746","key":"4862_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/s0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094\u20131108. https:\/\/doi.org\/10.1016\/s0140-6736(10)60826-4","journal-title":"Lancet"},{"issue":"11","key":"4862_CR2","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/art.39783","volume":"68","author":"Y Maeda","year":"2016","unstructured":"Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K et al (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 68(11):2646\u20132661. https:\/\/doi.org\/10.1002\/art.39783","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4862_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2019-215743","volume":"79","author":"T Kishikawa","year":"2020","unstructured":"Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M et al (2020) Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 79(1):103\u2013111. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215743","journal-title":"Ann Rheum Dis"},{"issue":"7488","key":"4862_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376\u2013381. https:\/\/doi.org\/10.1038\/nature12873","journal-title":"Nature"},{"issue":"4","key":"4862_CR5","doi-asserted-by":"publisher","first-page":"e0122121","DOI":"10.1371\/journal.pone.0122121","volume":"10","author":"M Hashimoto","year":"2015","unstructured":"Hashimoto M, Yamazaki T, Hamaguchi M, Morimoto T, Yamori M, Asai K et al (2015) Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS ONE 10(4):e0122121. https:\/\/doi.org\/10.1371\/journal.pone.0122121","journal-title":"PLoS ONE"},{"issue":"9","key":"4862_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162\u20131167. https:\/\/doi.org\/10.1136\/ard.2006.068064","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"4862_CR7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"issue":"6","key":"4862_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/1744666x.2017.1295850","volume":"13","author":"M Narazaki","year":"2017","unstructured":"Narazaki M, Tanaka T, Kishimoto T (2017) The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol 13(6):535\u2013551. https:\/\/doi.org\/10.1080\/1744666x.2017.1295850","journal-title":"Expert Rev Clin Immunol"},{"issue":"10042","key":"4862_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0140-6736(16)30363-4","volume":"388","author":"JWJ Bijlsma","year":"2016","unstructured":"Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Peth\u00f6-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042):343\u2013355. https:\/\/doi.org\/10.1016\/s0140-6736(16)30363-4","journal-title":"Lancet"},{"issue":"5","key":"4862_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/ard.2006.066704","volume":"66","author":"SP Linn-Rasker","year":"2007","unstructured":"Linn-Rasker SP, van der Helm-van Mil AH, Breedveld FC, Huizinga TW (2007) Arthritis of the large joints\u2014in particular, the knee\u2014at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis. Ann Rheum Dis 66(5):646\u2013650. https:\/\/doi.org\/10.1136\/ard.2006.066704","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4862_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13075-017-1387-9","volume":"19","author":"J Nakagawa","year":"2017","unstructured":"Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T et al (2017) A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. Arthritis Res Ther 19(1):185. https:\/\/doi.org\/10.1186\/s13075-017-1387-9","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4862_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00000441-195608000-00004","volume":"232","author":"J Lansbury","year":"1956","unstructured":"Lansbury J, Haut DD (1956) Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci. 232(2):150\u2013155","journal-title":"Am J Med Sci."},{"issue":"1","key":"4862_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-018-1673-1","volume":"20","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M et al (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 20(1):165. https:\/\/doi.org\/10.1186\/s13075-018-1673-1","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4862_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-020-02232-w","volume":"22","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-na\u00efve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22(1):142. https:\/\/doi.org\/10.1186\/s13075-020-02232-w","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4862_CR15","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","volume":"39","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study. Clin Rheumatol 39(9):2563\u20132572. https:\/\/doi.org\/10.1007\/s10067-020-05015-5","journal-title":"Clin Rheumatol"},{"key":"4862_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04660-y","author":"S Jinno","year":"2020","unstructured":"Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W et al (2020) Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-020-04660-y","journal-title":"Rheumatol Int"},{"issue":"3","key":"4862_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4862_CR18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569\u20132581. https:\/\/doi.org\/10.1002\/art.27584","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4862_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/art.1780300603","volume":"30","author":"PW Thompson","year":"1987","unstructured":"Thompson PW, Silman AJ, Kirwan JR, Currey HL (1987) Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 30(6):618\u2013623. https:\/\/doi.org\/10.1002\/art.1780300603","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4862_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.1780110411","volume":"11","author":"J Lansbury","year":"1968","unstructured":"Lansbury J (1968) Clinical appraisal of the activity index as a measure of rheumatoid activity. Arthritis Rheum 11(4):599\u2013604. https:\/\/doi.org\/10.1002\/art.1780110411","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4862_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2362.1991.tb01398.x","volume":"21","author":"I Holt","year":"1991","unstructured":"Holt I, Cooper RG, Hopkins SJ (1991) Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Investig 21(5):479\u2013484. https:\/\/doi.org\/10.1111\/j.1365-2362.1991.tb01398.x","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"4862_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000164393","volume":"55","author":"DY Chen","year":"2009","unstructured":"Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ (2009) Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55(3):250\u2013258. https:\/\/doi.org\/10.1159\/000164393","journal-title":"Gerontology"},{"issue":"7","key":"4862_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/art.1780380713","volume":"38","author":"Y Yoshihara","year":"1995","unstructured":"Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38(7):969\u2013975. https:\/\/doi.org\/10.1002\/art.1780380713","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4862_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/bf02249017","volume":"13","author":"S Sasaki","year":"1994","unstructured":"Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13(2):228\u2013233. https:\/\/doi.org\/10.1007\/bf02249017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4862_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3109\/14397595.2014.888794","volume":"24","author":"M Gorai","year":"2014","unstructured":"Gorai M, Ogasawara M, Matsuki Y, Yamada Y, Murayama G, Sugisaki N et al (2014) Weighting with the Lansbury Articular Index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients. Mod Rheumatol 24(6):915\u2013919. https:\/\/doi.org\/10.3109\/14397595.2014.888794","journal-title":"Mod Rheumatol"},{"issue":"11","key":"4862_CR26","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00264-017-3634-8","volume":"41","author":"M Lipina","year":"2017","unstructured":"Lipina M, Makarov M, Makarov S, Novikov A (2017) The degree of cartilage degradation assessed by serum biomarker levels changes after arthroscopic knee synovectomy in rheumatoid arthritis patients. Int Orthop 41(11):2259\u20132264. https:\/\/doi.org\/10.1007\/s00264-017-3634-8","journal-title":"Int Orthop"},{"issue":"4","key":"4862_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1043\/1543-2165(2007)131[563:Slomms]2.0.Co;2","volume":"131","author":"A Kobayashi","year":"2007","unstructured":"Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K et al (2007) Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 131(4):563\u2013570. https:\/\/doi.org\/10.1043\/1543-2165(2007)131[563:Slomms]2.0.Co;2","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"4862_CR28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acr.22765","volume":"68","author":"J Wang","year":"2016","unstructured":"Wang J, Devenport J, Low JM, Yu D, Hitraya E (2016) Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(6):882\u2013885. https:\/\/doi.org\/10.1002\/acr.22765","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"4862_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/ard.2009.113100","volume":"69","author":"W Zhang","year":"2010","unstructured":"Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B et al (2010) EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 69(3):483\u2013489. https:\/\/doi.org\/10.1136\/ard.2009.113100","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4862_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0036933015619588","volume":"61","author":"SM Hussain","year":"2016","unstructured":"Hussain SM, Neilly DW, Baliga S, Patil S, Meek R (2016) Knee osteoarthritis: a review of management options. Scott Med J 61(1):7\u201316. https:\/\/doi.org\/10.1177\/0036933015619588","journal-title":"Scott Med J"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04862-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T09:07:11Z","timestamp":1622279231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04862-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["4862"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04862-y","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"YM received a research grant and\/or speaker fee from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol Myers Squibb, and Mitsubishi Tanabe Pharma Corporation. TH received a speaker fee from GlaxoSmithKline, Chugai, Eisai, Eli Lilly and NIPPON SHINYAKU. KE is affiliated with the department, which is supported by Taisho. KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan. K.E. has received payments for lectures from Abbie, Asahi-Kasei, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, Ono Pharmaceutical, Sanofi and UCB Japan. MH belong to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi-Tanabe, Chugai, UCB Japan, AYUMI and Asahi-Kasei). MH has received a research and\/or speaker fee from Bristol-Meyers, Eisai, Ely Lilly, and Tanabe-Mitsubishi. JS reports personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Asahi-Kasei Corporation, personal fees from Eli Lilly and Company, personal fees from AbbVie GK. KM received a research grant from Eisai. AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi Tanabe, Asahi-Kasei and Takeda. AK received a research grant and\/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbie, Bristol-Myers Squibb, Ono Pharmaceutical and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}